Halozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Halozyme Therapeutics (NASDAQ:HALO) had its price objective raised by research analysts at JPMorgan Chase & Co. from $70.00 to $78.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential downside of 28.99% from the company’s current price.

HALO has been the topic of a number of other reports. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. TD Cowen lifted their target price on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. HC Wainwright increased their price target on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $94.00.

Halozyme Therapeutics Trading Down 0.9%

Shares of NASDAQ HALO traded down $0.95 during mid-day trading on Thursday, reaching $109.84. The company had a trading volume of 2,490,327 shares, compared to its average volume of 1,934,144. The stock has a market cap of $12.47 billion, a price-to-earnings ratio of 32.79, a price-to-earnings-growth ratio of 0.42 and a beta of 0.88. Halozyme Therapeutics has a 52 week low of $61.22 and a 52 week high of $116.85. The business’s 50-day moving average is $105.11 and its 200-day moving average is $82.53. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. Halozyme Therapeutics’s revenue was up 47.7% compared to the same quarter last year. During the same period last year, the company posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities analysts expect that Halozyme Therapeutics will post 8.25 earnings per share for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Matthew Posard sold 18,996 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the completion of the sale, the director owned 58,839 shares of the company’s stock, valued at $6,339,313.86. This trade represents a 24.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the sale, the director owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 85,852 shares of company stock worth $9,158,446 in the last ninety days. 2.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors have recently modified their holdings of HALO. Congress Asset Management Co. boosted its holdings in Halozyme Therapeutics by 85.6% in the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock valued at $251,890,000 after purchasing an additional 1,052,509 shares during the period. Bank of America Corp DE purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $214,504,000. William Blair Investment Management LLC purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $196,540,000. Royal London Asset Management Ltd. grew its position in shares of Halozyme Therapeutics by 12.4% during the second quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock worth $141,732,000 after buying an additional 200,262 shares in the last quarter. Finally, Jupiter Topco LLC acquired a new position in shares of Halozyme Therapeutics during the second quarter worth about $105,570,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: A Dutch court ordered Merck to stop manufacturing, selling, importing, or stocking the subcutaneous version of Keytruda in eight European markets: Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands. The ruling found Merck infringed Halozyme’s EP622 patent, strengthening Halozyme’s negotiating position and potentially protecting future royalty and licensing economics. Halozyme Wins Injunction Stopping Manufacture and Sale of Merck’s Keytruda SC in Multiple European Markets
• Positive Sentiment: Halozyme expanded its global ENHANZE collaboration with argenx from six to eight exclusive targets. The additional programs could generate development and commercial milestones, royalties, and long-term revenue growth, building on the successful VYVGART Hytrulo partnership. Halozyme Announces Expansion of Global Collaboration and License Agreement With argenx
• Neutral Sentiment: The Keytruda injunction is a meaningful legal win, but Merck could appeal or pursue other regulatory and legal strategies. The ruling’s ultimate financial impact will depend on its duration, geographic scope, and any resulting licensing agreement. Halozyme Granted Another Injunction Against Merck in Keytruda Patent Case

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.